30
Apr
2020

Share

Reporting season roundup

Every quarter when reporting season rolls around, there are always new insights gleaned that can provide a broader read-through on emerging trends. Perhaps with the uncertainty from the COVID-19 (C19) pandemic, this reporting season will be watched for clues more eagerly than usual. We will provide some interesting tidbits which give some colour around how companies are faring in today’s uncertain environment.

Hospitals doing worse than you would think

Hospital revenues must be benefiting from the influx of COVID-19 patients who require treatment, right? In fact, it’s the precise opposite. Typically, the bulk of hospital revenues in the US revolve around planned visits, and these high margin elective procedures such as orthopedic and heart procedures can account for the bulk of a hospital’s revenues. The C19 pandemic has seen an enormous decline in elective procedures as hospital facilities have been reprioritized for coronavirus patients in order to help expand intensive care capacity. The issue is that infectious disease and intensive respiratory treatments are less profitable, requiring isolations, around-the-clock care, and expensive equipment.

For example, HCA Healthcare (NYSE: HCA) in their recent earnings call highlighted the extent to which elective procedure volumes have fallen away: “Our hospital-based outpatient surgeries are running about 70 per cent below our prior year as most elective procedures have been deferred.” A further issue is that these lost revenues from elective procedures will not be fully recovered once coronavirus case volumes improve, given the limited hospital capacity that will be unable to accommodate months of deferred elective procedures.

Consumer products a mixed bag

A company such as Kimberly-Clark (NYSE: KMB) has been faring well during the pandemic. Its Q1 sales increased 8 per cent year-on-year, with organic sales up 11 per cent year-on-year. Consumers have been stocking up on tissues which has been to the enormous benefit of KMB: “Volumes were up 8 per cent including significant shipments to support consumer stock up related to the COVID-19 outbreak. That stock up occurred in all major geographies and benefited all three business segments, in particular Consumer Tissue”. While there might be a reversal of this dynamic later in FY19, the company believes that we could see an increase in tissue consumption during shelter-in-place periods which again would benefit KMB.

Coca-Cola (NYSE: KO) is a consumer products stalwart that has not fared nearly as well, given the sharp decline in away-from-home purchase occasions: “For context, if we look at our April month to-date trends, we are seeing volumes down globally approximately 25 per cent, driven by the sharp declines in our away-from-home businesses.”

Airlines are (unsurprisingly) struggling

Looking at a company such as Delta Air Lines (NYSE: DAL), it is facing unprecedented revenue declines as many flights have been cancelled.  DAL has had to raise significant capital to bolster its liquidity: “Since early March, we have raised $5.4 billion in new financing and will likely raise several billion more this quarter…And while this will help ensure we have liquidity to weather the crisis, with a the more than 90% expected reduction in revenues this quarter, we needed to quickly address cost to stem cash burn.”

“Right now, 37,000 employees, more than one-third of our workforce, have elected to take voluntary unpaid leaves ranging from 30 days to one year…This is helping reduce our daily cash burn which started at $100 million per day in March, down to $50 million a day starting next month in May.” That is a staggering amount of daily cash burn, even after the workforce reduction. For context, DAL ended the quarter with $6 billion in cash. At the current rate of cash burn, DAL will have burned through all of its cash in just four months. While it’s possible that lockdowns will be lifted in that time frame, will consumers be willing to resume air travel as per usual, or will they be reluctant to share a small enclosed cabin with a group of strangers? This will have serious implications for the future viability of a company such as DAL.

While most companies are being hard hit by the economic impacts from C19, there are some bright spots emerging from this reporting season. Gaining insights from this reporting season will be crucial in sharpening our understanding of: (i) the nuanced ways in which the C19 pandemic might affect different types of businesses; and (ii) the likely future financial outcomes for these businesses in terms of revenues and earnings power.

Our Funds

The Montgomery Fund

  • AUSTRALIA/NZ
  • Concentrated high conviction equities
  • From $25,000
Learn More

Montgomery Global Fund

  • GLOBAL
  • Concentrated high conviction equities
  • From $25,000
Learn More

Montaka Global Access Fund

  • GLOBAL
  • Access long/short global equity portfolio
  • From $50,000
Learn More

Montgomery Global Equities Fund (ASX:MOGL)

  • GLOBAL
  • Concentrated high conviction equities
  • No minimum investment - see your broker limits
Learn More

Montgomery Small Companies Fund

  • AUSTRALIA/NZ
  • Concentrated high conviction equities
  • From $25,000
Learn More
Close

Our Funds

Concentrated High Conviction Equities

Listed

Montgomery Global Equities Fund (ASX:MOGL)

Global
Available on the ASX as an Exchange Traded Managed Fund, invests in 15 to 30 quality global businesses for long-term capital growth with a target distribution yield of 4.5% per annum. Mirrors the strategy of the Montgomery Global Fund.
Unlisted From $25,000

Montgomery Global Fund

Global
Invests in 15 to 30 quality global businesses for long-term capital growth. Priced daily. Mirrors the strategy of the Montgomery Global Equities Fund (ASX:MOGL).
Unlisted from $25,000

The Montgomery Fund

Australia/NZ
Aims to provide long-term growth and income by investing in 20 to 40 high-quality Australian and New Zealand businesses trading at attractive valuations. Priced daily.
New Fund

Montgomery Small Companies Fund

Australia/NZ
Aims to provide long-term growth by investing in 30 to 50 high quality, undervalued, Australian and NZ small and emerging companies with strong growth potential. Priced daily.
Unlisted from $1 Million

The Montgomery [Private] Fund

Australia/NZ
Seeks to deliver absolute returns from a portfolio of high-quality Australian and New Zealand businesses. Capital preservation is paramount. By invitation only.

Alternate Equity Strategies

Unlisted from $50,000

Montaka Global Access Fund

Global
Aims to generate materially higher risk-adjusted returns, net of fees, than is generally available in the equities market over the medium term. Priced monthly. Provides retail investors access to the Montaka Global Fund.
Unlisted from $1million

Montaka Global 130/30 Fund

Global
Provides the opportunity to benefit from both the gains of extraordinary businesses and the declines of deteriorating businesses through a global equity active extension strategy, which has the potential to significantly outperform the broader equities market over time. Seeks to generate double-digit annual average returns, net of fees. Daily priced.
Unlisted From $1 Million

Montaka Global Fund

Global
Aims to generate materially higher risk-adjusted returns, net of fees, than is generally available in the equities market over the medium term. By invitation only.